Drug intelligence / Profile preview

KEPTIDE

Development stage: Preclinical
Lead developer: Sotira
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

KEPTIDE is a virus attachment inhibitor developed by Sotira SAS for the treatment of COVID-19. It is designed to inhibit the interaction between the SARS-CoV-2 spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2), thereby preventing viral entry into host cells. The drug acts as an ACE2 inhibitory motif of the spike protein and is currently in preclinical development for infectious and respiratory diseases, specifically targeting COVID-19[2].

Brand names: KEPTIDE
Other names: KEPTIDE Covid

Targets

ACE2 (Angiotensin-converting enzyme 2)

Beyond the preview

Go deeper on KEPTIDE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KEPTIDE.

Explore the full profile